Overview

Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy, safety and tolerance of long-acting risperidone when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
Phase:
Phase 4
Details
Lead Sponsor:
Janssen-Cilag Ltd.
Treatments:
Antipsychotic Agents
Risperidone